Patrys today announced the appointment of Dr Rebecca Tunstall to the role of Vice President, Corporate Development. As a key member of the Patrys executive team, Dr Tunstall will be focusing on preparations for the Company’s deoxymab clinical trials when she joins on May 16.
Rebecca comes with an impressive resume of experience in clinical development and stakeholder engagement. She spent 13 years with GlaxoSmithKline, where she held various leadership roles, and was deeply involved in the company’s oncology clinical research and development program. More recently, Rebecca held the role of Senior Director of Stakeholder Engagement at MTPConnect, where she built strong relationships with industry, government, regulators and research partners, both in Australia, and internationally.
Patrys CEO and MD, Dr James Campbell said:
“We are delighted to have been able to attract Rebecca to Patrys, and will benefit greatly from her experience and insights as we approach the clinic. Rebecca’s role will also encompass a range of corporate activities as Patrys builds a strong platform for growth in the coming year. Rebecca’s drive, experience, intellect and enthusiasm make her a perfect fit for the Patrys team, and we are delighted to welcome her into the Company.”